Drug manufacturer, Cephalon, will pay $425 million in a civil settlement over off-label drug marketing of three of its popular drugs. The three drugs were marketed for uses other than what the FDA (Food and Drug Administration) approved them for. Cephalon stated Monday, September 29, 2008 that in addition to the $425 million, it would be $12 million in interest.
While doctors can prescribe drugs for off-label usage, the drug maker cannot promote the drug for off-label uses.
The three drugs were Actiq, Gabitril and Provigil. Actiq was marketed for migraines and various injuries. Gabitril is an anti-epilepsy drug and Provigil is prescribed for narcolepsy.
The drug company has also pleaded guilty to one count of distribution of misbranded drugs.